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Abstract 
200 million people worldwide are living with a thyroid disorder related to a hormonal imbalance.  
Symptoms of this imbalance include deviations from normal heart rates and metabolic rates.  A chemical 
messenger known as T3 has been shown to raise cardiac and metabolic rates, but this takes place on a 
timescale of hours.  However, recent discoveries have revealed that a different thyroid hormone known 
as T1AM is capable of affecting some of these same physiological conditions in a matter of minutes.  
T1AM is a potent, selective agonist for the Trace Amine Associated Receptor (TAAR). Several studies 
have probed the structural basis of T1AM activation, but these studies have not yet provided a complete 
picture.  Based on these findings, we have developed a new molecular scaffold that incorporates key 
structural features in a conformationally-restricted arrangement.  For example, the incorporation of a 
six carbon ring in our target compounds will confine the location of the amine and even create multiple 
stereocenters.  Furthermore, several chiral locations on this scaffold will have structural variability.  To 
date, our research has focused on optimizing the reactions that produce 3-nitro-2H-chromenes, the 
chemical precursors to these target compounds. The successful production of a panel of these 
chromenes has set the stage for subsequent reactions that will allow us to generate many T1AM 
analogues.  By understanding the regulation of TAAR we may gain a greater understanding of its role in 
biology and human physiology. 
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Figure 3.  3-Iodothyronamine (T1AM) 
Figure 2.  3,5,3’-Triidothyronine (T3) 
Figure 1.  Thyroxine (T4) 
Background 
The thyroid gland in vertebrates regulates normal physiology by 
secreting hormones, the predominant one being Thyroxine (T4, 
figure 1).  In target tissues T4 is modified by the removal of an 
iodine atom to generate 3,5,3’-triiodothyronine (T3, figure 2), a 
high affinity ligand for nuclear receptors TRα and TRβ (Scanlan 
2004).  The effects of T3 include increased heart rate, increased 
metabolic rate, and raised core body temperature.  Because the 
effects of T3 are communicated through a transcription 
pathway, they are manifested over a period of hours or days 
(Scanlan 2004).   Overproduction of T3 is known as 
hyperthyroidism and is a common hormonal imbalance marked by increasing cardiac rate, metabolic 
rate, and core body temperature. 
 T3 can be modified still further by decarboxylation and the removal of two more iodine atoms to 
form 3-iodothyronamine (T1AM, figure 3), another hormone with an important role in vertebrate 
homeostasis.  When T1AM was administered to mice, they 
showed immediate inactivity, ptosis (drooping eyelids) and 
reduced body temperature.  Furthermore, the injection of 
T1AM into isolated rat hearts induced bradycardia in 
approximately ten minutes (Scanlan 2004).  These effects constitute the opposite of T3 but occur in a 
matter of minutes, an indication that T1AM communicates through a direct pathway, unlike that of T3.  
Thus it came as no surprise when T1AM was shown to not have an affinity for the receptors TRα or TRβ.  
Instead, administering T1AM to HEK293 cells expressing the rat Trace Amine Associated Receptor 
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(rTAAR) resulted in cAMP accumulation (Scanlan 2004).  Further tests confirmed that T1AM does indeed 
bind preferentially to TAAR from species of rats and mice (mTAAR), while T3 and T4 do not (Scanlan 
2004).  Based on these findings, it is believed that TAAR is responsible for communicating the effects of 
T1AM such as ptosis and bradycardia in mice. 
 The Trace Amine Associated Receptor is a G protein-coupled receptor (GPCR) similar to β2 
adrenergic (β2AR), dopamine, and serotonin receptors.  Since these receptors all belong to the same 
subfamily of class A rhodopsin-like GPCRs, the 
structure of β2AR can serve as an model for 
understanding the structure of TAAR (Tan 2008).  A 
GPCR like β2AR is composed of seven transmembrane 
(TM) proteins and contains a binding site located 
among TM 3, 5, 6, and 7 (figure 4).  Projecting from 
TM1 there is an amino terminus, and TM7 ends in a 
carboxy terminus (Tan 2008). 
 In the inactive state of β2AR, there is ionic lock 
between TM6 and TM3 composed of a glutamic acid residue 
in TM6 (E6.30) and aspartic acid and arginine residues 
(D3.49 and R3.50) in TM3 (Tan 2008).  When an agonist 
enters the binding pocket, it induces a conformational 
change that breaks this ionic lock, allowing TM6 to pivot 
away from TM3 (figure 5).  As a result, the G protein 
recognition sites on the intracellular surface of the receptor 
are exposed, initiating a signaling cascade (Tan 2008).  Since 
Figure 4.  Cross Section of GPCR 
Figure 5.  Active Conformation of β2AR 
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TAAR contains the same pertinent amino acid residues, the mechanism for agonist binding likely occurs 
the same way.  Interestingly, binding is not simply a one step process but rather a sequence of 
increasing interactions between the agonist and intermediate conformational states of the receptor that 
culminate when the fully active state is reached (Tan 2008).  TAAR may prove to have similarly complex 
ligand receptor interactions. 
 To better understand these interactions, the structure activity relationship (SAR) of rTAAR and 
mTAAR was probed by various synthetic T1AM analogues.  Since one of the distinguishing features of 
T1AM relative to T3 is the number and location of iodine atoms, thyronamines were synthesized with 
anywhere from zero to four iodine atoms at various locations on the aryl rings.  It was found that any 
change to the number or position of iodine atoms relative to T1AM reduced TAAR activation (Hart 
2006).  Still, a T1AM analogue without any iodine atoms (T0AM) did exhibit enough TAAR activation to 
serve as template for further SAR investigations.  In addition, 
removal of the hydroxyl from T0AM (figure 6) was beneficial 
for both rTAAR and mTAAR affinity relative to T0AM (Hart 
2006).  This established a convenient, elementary scaffold for 
variance in future analogues (figure 6). 
  Two different sites of modification relative to this scaffold were the bridges, one a biaryl ether 
connecting the two rings and the other an ethyl group supporting the amine.  Lengthening the biaryl 
ether by adding methylene groups generally improved mTAAR activation but was detrimental to rTAAR 
activation (Hart 2006).  Interestingly, when a long 
enough bridge had been reached (figure 7), 
mTAAR and rTAAR activation stabilized, 
suggesting that the compound was able to adopt 
Figure 6.  New Elementary Scaffold 
Figure 7.  Long Biaryl Bridge 
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whatever conformation best suited the receptor.  Based on these results, the original biaryl ether bridge 
appeared to be sufficient for future analogues.  Modifications were also made to the ethyl bridge 
supporting the amine by attaching an amide to the ring and adjusting the linkage length to the amine, as 
in figure 8.  Generally, these compounds were poor agonists for 
both mTAAR and rTAAR (Tan 2007), although bridges of 
sufficiently long length gradually improved activation potential, 
again suggesting that enough flexibility was achieved to adopt 
whatever conformation was needed to match the TAAR binding 
site.  Preserving the original bridge supporting the amine in T1AM was the most rational structure for 
further agonists. 
 One final modification of obvious significance is the basic amine.  Replacing the amine with a 
hydroxyl group abolished rTAAR and mTAAR affinity, demonstrating that this functional group is 
essential for TAAR activation (Hart 2006).  Different alkylation 
states of the amine were also explored.  In general, 
monomethylation (figure 9) was tolerated for both rTAAR and 
mTAAR, but longer alkyl chains and dimethylation of any sort were 
detrimental (Hart 2006). 
 These findings provided a foundation for developing rTAAR superagonists, or compounds that 
have an affinity for the receptor that exceeds T1AM.  The rational basis for making further modifications 
involved a proposed binding orientation and its surrounding amino acid residues in rTAAR.  Appending a 
phenyl group to the carbon in the β position to the amine provided a strategic location for attaching 
polar functional groups to interact with asparagines (N7.35 and N7.39), methionine (M6.55) and 
cysteine (C6.54) (Tan 2008).  This new structural scaffold, shown in figure 10, exhibited unprecedented 
Figure 8.  Poor TAAR Agonist 
Figure 9.  Monomethylation 
Lehmann 7 
 
affinity for rTAAR.  Interestingly, monomethylation of the amine 
also improved activation for this compound (Tan 2008).  This 
method of design, introducing functional groups to accommodate 
the residues surrounding a proposed binding orientation, was 
very successful at generating superagonists. 
 Another avenue of SAR research involves antagonists, compounds that inhibit receptor 
activation.  Antagonists are structurally similar to agonists since they still must have an affinity for the 
receptor, but they differ in key ways in order to prevent activation 
upon binding.  Figure 11 shows a potent rTAAR antagonist that 
contains two crucial structural modifications from the 
superagonist scaffold.  First of all, the R group has been apended 
in a precise location where it can interfere with the motion of the 
rotamer toggle switch.  This steric obstruction encumbers the 
conformational change that would normally accompany activation.  As a result, compounds containing 
especially bulky R groups, such as pentane or hexane ethers, were the most capable of sterically 
impeding this motion and performed the best as antagonists.  The second essential modification was 
repositioning the phenyl ether, which was necessary to eliminate the symmetry of the molecule and 
restrict the binding orientation of the compound.  Antagonists based on this structure exhibited 
inhibition of T1AM activation in competition assays, albiet in modest concentrations (Tan 2008). 
 Based on all these SAR studies, we have developed a novel molecular scaffold that incorporates 
these components in a new arrangement (figure 12).  Essential features including the basic amine and 
biaryl linkage have been conserved, while nonessential moities such as the hydroxyl group and iodine 
have not.  However, the most significant structural revision is the cyclization of the ring connected to the 
Figure 10.  rTAAR Superagonist 
Figure 11.  R = OHex, OPent 
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α carbon to the amine.  This increases the rigidity of the 
compound and confines the location of the amine, which 
can be controlled even further because it is attached to a 
chiral carbon.  Two crucial points of variation also exist on 
this scaffold at the R1 and R2 positions.  Based on past 
superagonist structures, appending a phenyl ring at the R1 position provides a location for polar 
functional groups that can have interactions with the receptor.  Furthermore, the variability at the R2 
position could be exploited to generated antagonists by appending bulky groups such as hexane ethers.  
The potential for stereoisomers involving three chiral centers, at the amine, R1, and R2 positions, allows 
us to exert a tremendous amount of control over the exact spatial positioning of all these groups. 
Results and Discussion 
 Our laboratory work has been focused on optimizing the synthesis of this scaffold (scheme 1).  
Figure 12.  Novel Scaffold 
Scheme 1.  Retrosynthetic Plan 
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The first step in this strategy is the production of 3-nitro-2H-chromenes, compounds that contain nitro 
groups that serve as precursors to amines.  These nitrochromenes also have hydroxyl groups that will 
later facilitate the attachment of phenyl ethers. To date, two different reactions have been employed to 
generate a panel of nitrochromenes varying at the R2 position and at the location of the –OH group that 
will later be replaced by a phenyl ether. 
 The first successful procedure for synthesizing these nitrochromenes utilizes the same 
substrates as shown in scheme 1.  Salicylaldehyde (1 eq.) and nitroethanol (1.6 eq.) are to be mixed with 
di-n-butylammonium chloride (DBAC, 0.5 eq.) in the solvent isopentyl acetate (Dauzonne 1984).  Instead 
of using DBAC, we employed dibutylamine and then generated HCl in situ by mixing acetyl chloride and 
isopentanol.  Another important factor was the utilization of a Dean Stark apparatus, which was 
essential for collecting the water produced by the reaction.  By Le Chatelier’s Principle, this removal of 
product helped push the reaction toward completion.  We were unable to duplicate the yield reported 
in this paper, generating only a 16% yield instead of the reported 50%.  Next, this reaction was applied 
to different substrates, including 2,4-dihydroxybenzaldehyde and 2,5-dihydroxybenzaldehyde, with the 
yield for the latter reaching 24.4%. 
 The second successful method of nitrochromene formation was based on the Morita-Baylis-
Hillman reaction (scheme 2).  According to the literature, the best mixture for this reaction was 1 
equivalent of the nitroalkene, 1 equivalent of formaldehyde, 1 equivalent of imidazole, and 10 mol % of 
Scheme 2.  Morita-Baylis-Hillman Based Nitrochromene formation 
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anthranilic acid in THF at room temperature (Rastogi 2004).  We changed this procedure significantly by 
employing salicylaldehyde instead of formaldehyde and refluxing the reaction in ethyl acetate and later 
propyl acetate (scheme 2).  These temperatures proved conducive to chromene formation and yields of 
approximately 20% were reached, although the product was difficult to purify by column 
chromatography because the reactants had the same Rf as the product.  We also discovered that using a 
Dean Stark apparatus to remove water improved yields for this reaction as well. 
 Another chromene formation tactic that we attempted was solvent free and facilitated by a 
regular household microwave (Scheme 3).  We were unable to generate any nitrochromenes by 
following the synthesis outlined in the article (Koussini 2008) or by making modifications including 
raising the amount of TBAB to a stoichiometric quantity and adjusting the microwaving time intervals.  
However, based on how the Dean Stark apparatus was necessary for removing water from the one-pot 
synthesis reaction and Morita-Baylis-Hillman reaction, adding molecular sieves to remove water from 
this reaction might push it to completion in a similar way.  We intend to try this in the future while we 
continue to optimize the other chromene formation reactions that have succeeded. 
 The last step in scheme 1 is reduction of the amine, but testing this chemistry on a model 
system provided a cheaper more precedented way to optimize it (scheme 4).  The literature used 3,4-
X 
Scheme 3.  Microwave Assisted Chromene Formation 
Scheme 4.  Model System of Hydrogenation 
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methylenedioxy-β-nitrostyrene (Kohno 1990), a trans-nitrostyrene with a different pattern of aromatic 
substitution than the substrate shown in scheme 4.  In addition, the specific catalyst called for, 5% Pd/C 
K-type was not readily available, so 10% Pd/C was used instead.  After the reaction was stopped, boc 
anhydride was added to protect the amine from decomposition.  Even with all of these modifications, 
promising peaks were still visible on NMR, although further optimization and purification steps are 
required before any yields can be reported. 
 The success of the first stage of this synthesis includes the utilization of two different chromene 
formation reactions and the production of a panel of nitrochromenes.  Exploring the reduction of these 
nitrochromenes with a model system was the first step in converting these precursors into TAAR 
regulators.  However, much more still needs to be done.  Based on the retrosynthetic plan (scheme 1), 
several more reactions are required to append other moieties and complete the target scaffold.  These 
challenges will provide plenty of inquiries for further laboratory investigations over the next year. 
 
Conclusion and Future Directions 
 A very important step in the completion of this scaffold is replacement of the hydroxyl group 
with a phenyl ether, which is accomplished by a copper coupling reaction (scheme 5).  This chemistry 
Scheme 5.  Copper Coupling 
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has already been utilized in the lab, and will be extended in the nitrochromene case.  Still, the creation 
of novel TAAR regulators requires this structural alteration. 
 Conjugate addition to the nitrochromene provides variation at the R1 position, a modification 
that could be used to generate superagonists and lead antagonists.  One method of conjugate addition 
is organocatalytic malonate addition (scheme 6).  While the range of groups that can be added to 
nitroalkenes is limited, the literature on this reaction reports achievement of enantioselectivity (Chen 
2011).  The second method of conjugate addition that could be employed is organocopper addition, a 
multistep process inolving organometallics (scheme 7).  A wide variety of substrates are compatible with 
this reaction, providing a great potential for variation at a position that has already been utilized in the 
development of superagonists.  Enantioselectivity of this step will also be explored. 
 
Scheme 6.  Organocatalytic Malonate Addition (Michael Addition) 
 
 
 
Scheme 7.  Organocopper addition 
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 TAAR performs a crucial role in normal vertebrate physiology that is still being resolved.  Upon 
activation by the selective agonist T1AM, TAAR initiates rapid and acute effects on cardiac rate, 
metabolic rate, and body temperature.  SAR studies of this receptor with T1AM analogues have shown 
what structural features are essential for TAAR affinity, and rational molecular design based on binding 
orientation has led to highly effective agonists and antagonists.  We hope to produce novel TAAR 
regulators by incorporating these moieties into a rigid, conformationally-restricted scaffold.  Even 
though our synthesis has not been completed yet, the successful production of a panel of substituted 3-
nitro-2H-chromenes has provided many precursors for the creation diverse panel of target compounds.  
As we continue optimizing the synthesis of TAAR regulators, we expect to learn more about the nature 
of this important receptor. 
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Plans for Dissemination 
Presentations 
 Student Summer Showcase 
 2011 West Michigan Undergraduate Research Symposium at Van Andel 
 American Chemical Society National Meeting or a Council on Undergraduate Research Meeting- 
when data is sufficient 
Publication 
 When sufficient research has been completed, the S3 report will serve as the basis for 
submission to a peer-reviewed journal (e.g. Journal of Organic Chemistry or Journal of Medicinal 
Chemistry). 
 
